- 33. The method according to claim 29 wherein human rHuPSP94 (SEQ ID NO: 2) is administered in a dosage range from about 5 nanograms/kg/day to about 10 micrograms/kg/day.
- 34. The method according to claim 29 wherein said polypeptide is selected from the group consisting of the decapeptide as set forth in SEQ ID NO: 3, the polypeptide as set forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ ID NO: 5, the polypeptide as set forth in SEQ ID NO: 6, and mixtures thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.
- 35. The method according to claim 29 wherein said polypeptide is used with an anticancer drug.
- 36. The method of claim 35 wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
- 37. The method according to claim 29 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
- 38. The method according to claim 35 wherein said polypeptide is used with a pharmaceutically acceptable carrier.
- 39. The method according to claim 29 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
- 40. The method according to claim 35 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
- 41. The method according to claim 37 wherein said polypeptide is used with a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of said polypeptide.
- 42. The method according to claim 38 wherein said polypeptide is used with a time-release means selected from the group

-SUBSTITUTE PAGE 114-

forth in SEQ ID NO: 4, the polypeptide as set forth in SEQ ID NO: 5, the polypeptide as set forth in SEQ ID NO:6 and mixture(s) thereof, wherein said polypeptide is used in a dosage range from about 100 nanograms/kg/day to about 4 milligrams/kg/day.

- 74. A pharmaceutical composition according to claim 66 further comprising an anticancer drug.
- 75. A pharmaceutical composition according to claim 65, wherein said anticancer drug is selected from the group consisting of mitomycin, idarubicin, cisplatin, 5-fluoro-uracil, methotrexate, adriamycin, daunomycin, taxol, taxol derivative, and mixtures thereof.
- 76. A pharmaceutical composition as in claim 66, further comprising a time-release means selected from the group consisting of liposomes and polysaccharides for effecting continual dosing of the composition.
- 77. A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperlasia (BPH), comprising a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
- 78. A pharmaceutical composition for inhibiting the growth of a tumor in a patient, comprising a vector comprising the nucleotide sequence of SEQ ID NO: 9 and a pharmaceutically acceptable carrier.
- 79. A pharmaceutical composition for inhibiting the growth of a tumor in a patient suffering from prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperlasia (BPH), comprising a polynucleotide having at least 10 to 285 contiguous residues of SEQ ID No: 9 and a polynucleotide having at least 10 to 50 contiguous residues of SEQ ID NO: 9, and a pharmaceutically acceptable carrier.
- 80. A pharmaceutical composition for inhibing the growth of a tumor in a patient, comprising a polynucleotide selected from

-SUBSTITUTE PAGE 121-